文献速递细菌感染、耐药与抗菌药物

静脉磷霉素的临床证据:系统综述与荟萃分析

Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature.
PubMed 文献 · Clin Microbiol Infect · 2016-12-09

该系统综述与荟萃分析检索了PubMed、Cochrane图书馆及地方期刊,纳入128项研究共5527例接受静脉磷霉素治疗的成人和儿童患者,评估其临床与微生物学疗效、耐药发生及安全性。比较性试验中磷霉素与其他抗生素的临床疗效(OR 1.44,95%CI 0.96-2.15)和微生物学疗效(OR 1.28,95%CI 0.82-2.01)无显著差异;单药治疗期间耐药发生合并估计为3.4%(95%CI 1.8%-5.1%)。

要点

  • 静脉磷霉素与其他抗生素在比较性试验中临床和微生物学疗效无显著差异。
  • 单药治疗期间耐药发生合并估计为3.4%(95%CI 1.8%-5.1%)。
  • 安全性良好,不良事件通常轻微且无需停药。

核心结论

  • 静脉磷霉素具有长期有效且安全使用的历史,可在抗菌药物库中发挥重要作用,但仍需设计良好的随机对照试验。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Cochrane图书馆及地方期刊,纳入128项报告静脉磷霉素用于成人和儿童聚合数据的研究,排除单例报告。

主要发现

  • 共评估128项研究、5527例患者,磷霉素主要用于脓毒症/菌血症、尿路、呼吸道、骨与关节及中枢神经系统感染。
  • 比较性试验中磷霉素与其他抗生素的临床疗效无差异(OR 1.44,95%CI 0.96-2.15)。
  • 比较性试验中磷霉素与其他抗生素的微生物学疗效无差异(OR 1.28,95%CI 0.82-2.01)。
  • 单药治疗期间耐药发生的合并估计为3.4%(95%CI 1.8%-5.1%)。
  • 磷霉素安全性良好,不良事件通常轻微且无需停药。

关键数值与推荐

  • 临床疗效比较:OR 1.44(95%CI 0.96-2.15)。
  • 微生物学疗效比较:OR 1.28(95%CI 0.82-2.01)。
  • 单药治疗耐药发生合并估计:3.4%(95%CI 1.8%-5.1%)。

临床怎么用

  • 静脉磷霉素可用于脓毒症/菌血症、尿路、呼吸道、骨与关节及中枢神经系统感染。
  • 1990年后的研究聚焦于磷霉素联合β-内酰胺类或氨基糖苷类治疗多重耐药菌所致疑难感染。

局限性

  • 仍需设计良好的随机对照试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We conducted a systematic review and meta-analysis to summarize the clinical evidence and usage patterns of intravenous fosfomycin from its development to the present time. METHODS: PubMed, the Cochrane Library and local journals were searched for relevant studies reporting aggregated data of intravenous fosfomycin use in adults and children, with no restrictions regarding study design. Single case reports were excluded. Data were systematically abstracted for all included studies. Clinical and microbiological efficacy from randomized controlled and comparative observational studies were synthesized using meta-analysis to calculate pooled effect sizes. RESULTS: In all, 128 studies on intravenous fosfomycin in 5527 patients were evaluated. Fosfomycin was predominantly used for sepsis/bacteraemia, urinary tract, respiratory tract, bone and joint, and central nervous system infections. No difference in clinical (OR 1.44, 95% CI 0.96-2.15) or microbiological (OR 1.28, 95% CI 0.82-2.01) efficacy between fosfomycin and other antibiotics was observed in comparative trials. The pooled estimate for resistance development during fosfomycin monotherapy was 3.4% (95% CI 1.8%-5.1%). Fosfomycin showed a favourable safety profile, with generally mild adverse events not requiring discontinuation of treatment. Included studies explored intravenous fosfomycin as an anti-staphylococcal agent in monotherapy and combination therapy, whereas studies from 1990 focused on combination therapy (fosfoymcin + β-lactams or aminoglycosides) for challenging infections frequently caused by multidrug-resistant organisms. CONCLUSION: Intravenous fosfomycin can play a vital role in the antibiotic armamentarium, given its long history of effective and safe use. However, well-designed randomized controlled trials are still desired.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Grabein B, Graninger W, Rodríguez Baño J, et al. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2016. PMID: 27956267. doi:10.1016/j.cmi.2016.12.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。